Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV.

NATALIA LAUFER; JURGEN KURT ROCKSTROH

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY

EXPERT REVIEWS

Año: 2014 vol. 12 p. 157 - 164

1478-7210

Chronic HCV infection affects 130?170 million individuals worldwide and there are currently 34 million people living with HIV/AIDS. The aim of treatment of HCV is the elimination of the virus (sustained virological response). With development of drugs that specifically target HCV replication, direct-acting agents, sustained virological response rates have dramatically changed for genotype 1 infections. Challenges in the use of direct-acting agents in patients with HIV/HCV co-infection include the potential for drug?drug interactions between HIV and HCV drugs, additional drug toxicities and the need for therapy with IFN-a. Faldaprevir (FDV), previously known as BI 201335, is a second-wave HCV NS3/4A protease inhibitor with highly potent in vitro activity against HCV GT-1a/1b and improved pharmacokinetics suitable for once-daily dosing. FDV is currently in Phase III development. This article will review the pharmacology and pharmacodynamics of FDV, the efficacy and safety of the drug and explore possible future developments in the management of chronic hepatitis C infection, focusing on HIV/HCV co-infected patients.